Takeda Pharmaceutical (TAK) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $5.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$5.5M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about TAK filings

Are insiders buying or selling Takeda Pharmaceutical Co Ltd ADR (TAK) stock?

Net selling: insiders sold $5.5M and bought $0 of TAK stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $2.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Plump, Andrew Stewart (President, R&D), who sold $2.5M. The latest filing was on Nov 5, 2026.

Which members of Congress have traded TAK recently?

None. No member of Congress disclosed a TAK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this TAK smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

19 funds hold a position and insiders have been net selling.

Questions about TAK filings

Are insiders buying or selling Takeda Pharmaceutical Co Ltd ADR (TAK) stock?

Which members of Congress have traded TAK recently?

None. No member of Congress disclosed a TAK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this TAK smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$71.3M

Buys/Adds (3)

QR
Qube Research
Q2 2026 13F
$35.4M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
AQ
AQR
Q2 2026 13F
$7.9M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
JC
JPMorgan Chase
Q3 2026 13F
$24.4M
added

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 29, 2026

Earnings came in 64.5% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 29, 2026

Period ending

Sep 30, 2026

Earnings per share

$0.51+64.52% beat

$0.31 expected

Revenue (FY)

JPY 4.51T

Year ended Mar 31, 2026 · SEC filing

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 29, 2026	$0.51est. $0.31	+64.52%beat	Not on file	Not on file
Jun 30, 2026Reported Jul 30, 2026	$0.48est. $0.41	+17.07%beat	JPY 1.22TAlpha Vantage	+10.2%from JPY 1.11T
Mar 31, 2026Reported May 13, 2026	-$0.74Reported	No estimate	JPY 1.11TAlpha Vantage	+5.8%from JPY 1.05T
Dec 31, 2025Reported Jan 29, 2026	$0.21Reported	No estimate	JPY 1.21TAlpha Vantage	+6.0%from JPY 1.14T
Sep 30, 2025Reported Oct 30, 2025	-$0.03est. $0.15	-116.75%miss	JPY 1.11TAlpha Vantage	-5.4%from JPY 1.18T
Jun 30, 2025Reported Jul 30, 2025	$151.00est. $0.20	+$150.80beat	JPY 1.11TAlpha Vantage	-8.4%from JPY 1.21T
Mar 31, 2025Reported Jun 25, 2025	-$0.23est. -$0.17	-37.11%miss	JPY 1.05TAlpha Vantage	+0.2%from JPY 1.05T
Dec 31, 2024Reported Jan 30, 2025	$0.05est. $0.63	-92.41%miss	JPY 1.14TAlpha Vantage	+3.0%from JPY 1.11T

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $21.20
High: $21.34
Low: $21.08
Prev close: $20.84
52-wk high: $21.73
52-wk low: $13.39
Mkt cap: $67.48B
P/E: 301.7x
ROE: +0.6%
Fwd P/E: 12.7x
Beta: 0.08
Div yield: 2.92%
P/S: 0.0x
P/B: 1.4x
Profit margin: +0.9%
Op margin: +16.6%

Fundamentals

Is the business strong?

Richly priced and running thin margins.

Net margin: 0.9%
P/E: 301.71
Forward P/E: 12.72
Market cap: $67.5B

Valuation

P/S0.01
P/B1.42
Dividend yield2.9%

Quality

Operating margin16.6%
ROE0.6%
ROA3.3%

Growth

Beta0.08

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

65balanced

20D volatility

22%annualized

52-week range

$21.12

$13.39$21.73

20D support

$19.50recent floor

20D resistance

$21.73recent ceiling

Returns

5D -0.3%20D +8.6%60D +15.2%

Price vs moving averages

SMA20 +2.9%SMA50 +9.2%SMA200 +19.3%

Volume pace

1.09xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 29, 2026

$0.51est. $0.31

+64.52%

Not on file

Jun 30, 2026Jul 30, 2026

$0.48est. $0.41

+17.07%

JPY 1.22TAlpha Vantage

+10.2%from JPY 1.11T

Mar 31, 2026May 13, 2026

-$0.74Reported

No estimate

JPY 1.11TAlpha Vantage

+5.8%from JPY 1.05T

Dec 31, 2025Jan 29, 2026

$0.21Reported

No estimate

JPY 1.21TAlpha Vantage

+6.0%from JPY 1.14T

Sep 30, 2025Oct 30, 2025

-$0.03est. $0.15

-116.75%

JPY 1.11TAlpha Vantage

-5.4%from JPY 1.18T

Jun 30, 2025Jul 30, 2025

$151.00est. $0.20

+$150.80

JPY 1.11TAlpha Vantage

-8.4%from JPY 1.21T

Mar 31, 2025Jun 25, 2025

-$0.23est. -$0.17

-37.11%

JPY 1.05TAlpha Vantage

+0.2%from JPY 1.05T

Dec 31, 2024Jan 30, 2025

$0.05est. $0.63

-92.41%

JPY 1.14TAlpha Vantage

+3.0%from JPY 1.11T

Takeda Pharmaceutical Co Ltd ADR

Smart money at a glance

What do analysts expect?

Questions about TAK filings

Questions about TAK filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 64.5% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Takeda Pharmaceutical Co Ltd ADR

Smart money at a glance

What do analysts expect?

Questions about TAK filings

Questions about TAK filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 64.5% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Takeda Pharmaceutical Co Ltd ADR

Overview

Questions about TAK filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Takeda Pharmaceutical Co Ltd ADR

Overview

Questions about TAK filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.